Study summary · research use only
[New approaches to therapy in glomerulonephritis patients]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This report describes a treatment approach for chronic glomerulonephritis. The abstract states that before treatment it is desirable to determine drug sensitivity in vitro, and that in its absence chemotherapy should be preceded by immunomodulation with tactivin or thymalin and 3-5 sessions of plasmapheresis to stimulate drug sensitivity. Further described measures include prednisolone or cyclophosphamide intravenously for 3-5 days at a dose of 300-500 followed by oral administration, with active treatment lasting 4-8 weeks and maintenance for 1-2 years.
Abstract
Before starting treatment of chronic glomerulonephritis it is desirable to determine the patient's drug sensitivity in vitro because in the absence of such sensitivity chemotherapy should be preceded by immunomodulation with tactivin or thymalin and 3-5 sessions of plasmapheresis to stimulate drug sensitivity. Further measures include prednisolone or cyclophosphamide intravenously for 3-5 days in a dose 300-500 followed by oral administration. Active treatment lasts for 4-8 weeks. After that the patients receive maintenance for 1-2 years.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.